.
The first thing to note is that the oft repeated finding that the malignant cells of a tumour exhibit wide phenotypic and karyotypic heterogeneity is not incompatible with the concept that they all derive from a single transformed cell. The heterogeneity of the cancer cells comprising a tumour stems from karyotypic instability which is perhaps the most characteristic difference between cancer and normal cells. Not only is a failure in mitosis to share chromosomes equally between the two daughter cells much more frequent for malignant than for normal cells but in the case of malignant cells the progeny of unequal division commonly retain the capacity of unlimited proliferation and consequently must be heterogenous in phenotype.
The most compelling evidence for monoclonality comes from analyses of the gene products of malignant cells and these may be located on the surface, within the cell or secreted. With tumours of B-cell lineage, monoclonality is most easily established by the fact that all cells synthesise the same immunoglobulin. Recently the demonstration of unique DNA rearrangements of the antigen receptors has proved the monoclonality of most T-cell malignancies so far studied. For non-lymphoid cancers, studies of clonality have been based on the mosaicism which exists in normal tissues of women heterozygous for the two alleleic forms of the enzyme glucose-6-phosphate dehydrogenase, the gene for which is on the X-chromosome. The cells from tumours of such women are usually-though not invariably-composed predominantly of one of the alleles and therefore monoclonal. The existence of a specific karyotypic abnormality in all of the cells of a cancer or leukaemia have also been claimed as showing a clonal origin, but in view of the findings that a particular chromosome abnormality may be related to a particular malignancy, renders this type of evidence less convincing as evidence for monoclonality than the analysis of gene products. Taken together these studies suggest that many, if not most, cases of human cancer and leukaemia are monoclonal. It is tempting to interpret this as supporting both a clonal origin and the hypothesis that cancer is the consequence of a very rare and heritable event involving a single cell only. In other words the cause is a mutation or a sequence of mutations induced in one somatic cell. (Borek, 1982) although the same applies to chemical carcinogens or indeed "spontaneous" transformation. One Gray of X-rays given to embryonic cells in tissue culture causes of the order one cell in 104 to be transformed and after clonal expansion such a transformed cell will grow as a tumour in vivo. Yet clearly the carcinogenicity of X-rays for intact animals is many orders of magnitude less than would follow from the induction at the rate observed in vitro of a single malignant cell when one considers the number of cells capable of being transformed.
The discrepancy between the rate of induction of cancer in animals and of transformation of cells in vitro was seen by Burnet (1970) as evidence for the existence in animals of a mechanism which results in the selective destruction of cells exhibiting a transformed phenotype. Burnet was a most persuasive advocate of the hypothesis that specific T-cell acquired immunity was responsible for surveillance of potentially malignant cells but sadly experience with animals (and immunosuppressed patients) failed to reveal an increase in cancer incidence except when this could be directly attributable to viruses of DNA type when the surveillance was that of the viral infection as well as of the transformed cells (cf. Stutman, 1975) . More recently the role of eliminating transformed cells has been allocated to so call non-specific immune processes exerted by leukocytes and especially NK cells. However, as with surveillance by T-cells direct experimental data fails to support this concept (Fodstad et al., 1984) .
A way out of the conflict between the ease of cell transformation in vitro and the rarity of tumours in vivo is to abandon the concept that tumours arise from a single cell. The finding of monoclonality in clinically detectable cancer and leukaemia when more than 1010 cancer cells are present does not mean that initially the cancer arose from a single cell. Initially the malignant proliferation could be polyclonal and monoclonality could be a late event due to selection of cells from the different clones. Indeed, in chemically induced sarcomas of mice Woodruff et al. (1982) (Kaplan & Ozanne, 1983 lung to which they must have gained access via the arterial circulation. However one of the most striking aspects of the metastatic process is the peculiarity of the relative frequencies of metastases in different organs. This cannot be explained by haemodynamic factors and the concept of Paget (1889) that particular organs provide expecially favourable soil for tumour emboli which he likened to seed has found powerful support from clinical post mortem studies (cf. Willis, 1967) . These show that cancer cells that have passed beyond the lung into the arterial circulation grow selectively in certain organs. In experimental animals organ preference can be demonstrated by injecting cancer cells into the left ventricle (so as to avoid the filtering effect of the lung which arises if cells are given intravenously) whence they are distributed via the arterial circulation to all of the organs. Several investigations had shown that following this procedure few, if any, metastases occurred in gut and muscle which received the majority of the blood, but occurred instead in adrenal, bone, ovary and other organs that took only a small fraction of the cardiac output.
We have made a detailed study of the initial distribution, trapping, cell death and eventual incidence of metastases for three histologically different rat tumours following intracardiac injection of their cells . In our studies the proportion of the cells arrested in different organs paralleled the blood flow to the organs (i.e. the cells went where the blood went) but the probability that a cancer cell deposited in an organ causes a macroscopic metastasis varied very widely between different organs. Thus, one out of ten cells trapped in the adrenal caused a metastasis whereas in skeletal muscle the figure was one in 105. This organ preference does not have an immunological basis as the same distribution is seen in genetically athymic (nu/nu) rats and rats immunosuppressed with cyclosporin A. We have speculated that an isolated cancer cell is not capable of autonomous growth unless it finds itself in a tissue capable of supplying it with growth factors which act like TGFs, or which potentiate TGF. Once growth has started it will be self sustaining since a cluster of cancer cells will ensure the necessary concentration of TGF in the fluid around the metastasis.
The existence of dormant metastases in organs distant from the primary tumour could be similarly explained (Alexander, 1983) . In animal models the presence in the lung of dormant cancer cells which stemmed from blood borne spread from a distant primary tumour could be demonstrated by transplantation. In the lung the cells do not grow but when a cell suspension from the lung taken from animals from which the "primary" had been surgically removed a week previously, is injected into the peritoneal cavity then tumours indistinguishable from the "primary" grow out.
In view of the synergy between some tumour promoters, such as the phorbal esters, and polypeptide growth factors (Dicker & Rozengurt, 1978) it is conceivable that one part of the promotional component of carcinogenesis is that the promoter makes possible the proliferation in vivo of single or small numbers of transformed cells which in the absence of the promoter would not proliferate because the local TGF concentration is too low. Indeed, Rous's strategy when looking for a promotional phase in skin carcinogenesis was to induce division of initiated cells. (cf. Friedewald & Rous, 1944) . Also, the concept that more than one cell needs to undergo transformation before a tumour can develop is in some ways a re-expression of theories which saw cancer as a generalised tissue disorder. The evidence for this is compelling for bladder carcinoma and attention has recently been drawn to this old concept by Rubin (1984) in a critical analysis of the role of mutational events in carcinogenesis. I conclude that recent discoveries in the field of polypeptide growth factors and in particular their constitutive synthesis by malignant cells provides a biological framework in which the clonal growth of malignant cells in vitro can be reconciled with a hypothesis that in general tumours occurring in animals are not clonal in origin, but that their genesis requires the interaction and co-operation of several transformed cells. The monoclonality of macroscopic tumours need not reflect a clonal state at early stages of tumour development, so much as the cumulative effect of selective pressures upon polyclonal populations during active growth. P. Alexander CRC Medical Oncology Unit, University of Southampton, Southampton General Hospital, Southampton S049 4XY, Hants, UK.
